Replies to post #182179 on Biotech Values

[biomaven0]

>>Gilead will probably work out a deal with NICE for TAF regimes just like they came to an agreement with Sovaldi ?

I think it will be much harder for TAF than for Sovaldi. The delta to the next-best treatment is just so much smaller for TAF than for Sovaldi.

GILD will still very much be playing defense in HIV - slowing the decline is the best they can hope for.

Peter